AIM ImmunoTech (AIM) investor relations material

Company overview and business model

• Focuses on immuno-pharma, developing nucleic acids and natural interferon to enhance antiviral defense, with lead products Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa).

• Ampligen is being developed for late-stage pancreatic cancer and other cancers, viral diseases, and immune disorders; approved in Argentina for severe Chronic Fatigue Syndrome.

• Ongoing clinical trials for Ampligen in oncology, antiviral, and post-COVID fatigue applications, with a strategic focus on late-stage pancreatic cancer due to market potential and limited competition.

• Holds broad combination therapy patents and orphan drug exclusivity in the US, EU, and Japan for Ampligen.

Financial performance and metrics

• Stockholders' equity increased to $6.5 million after recent offerings, meeting NYSE American's $6.0 million minimum requirement.

• Last reported sale price of common stock was $0.52 per share on June 5, 2026.

• If all warrants are exercised for cash, gross proceeds could reach approximately $14.5 million.

• Company has a history of non-compliance with listing requirements but is currently compliant.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders.

• Proceeds from warrant exercises, if any, will be used for general corporate purposes and working capital.

• Management has broad discretion over use of any proceeds from warrant exercises.